Hostname: page-component-586b7cd67f-rdxmf Total loading time: 0 Render date: 2024-11-25T15:13:58.171Z Has data issue: false hasContentIssue false
  • English
  • Français

New approaches for the local prevention of osteoporotic fractures

Published online by Cambridge University Press:  19 March 2012

P. Janvier ,
V. Schnitzler ,
J.-M. Bouler ,
O. Gauthier ,
C. Despas ,
A. Walcarius ,
F. Fayon ,
D. Massiot ,
G. Montavon  and
C. Mellier
...Show all authors
P. Janvier
Affiliation:
Université de Nantes, CNRS, UMR 6230, CEISAM, UFR Sciences et Techniques, 2 Rue de la Houssinière, B.P. 92208, 44322 Nantes Cedex 3, France.
V. Schnitzler
Affiliation:
Université de Nantes, INSERM, UMR 791, LIOAD, Faculté de Chirurgie Dentaire, B.P. 84215, 44042 Nantes Cedex 1, France. Graftys SARL, Eiffel Park, Bâtiment D, 415 Rue Claude Nicolas Ledoux, Pôle d’Activités d’Aix en Provence, 13854 Aix en Provence Cedex 3, France.
J.-M. Bouler
Affiliation:
Université de Nantes, INSERM, UMR 791, LIOAD, Faculté de Chirurgie Dentaire, B.P. 84215, 44042 Nantes Cedex 1, France.
O. Gauthier
Affiliation:
Université de Nantes, INSERM, UMR 791, LIOAD, Faculté de Chirurgie Dentaire, B.P. 84215, 44042 Nantes Cedex 1, France.
C. Despas
Affiliation:
Nancy-Université, CNRS, UMR 7564, LCPME, 405 Rue de Vandoeuvre, 54600 Villers-lès-Nancy, France.
A. Walcarius
Affiliation:
Nancy-Université, CNRS, UMR 7564, LCPME, 405 Rue de Vandoeuvre, 54600 Villers-lès-Nancy, France.
F. Fayon
Affiliation:
CNRS, UPR 3079, CEMHTI, 1D Avenue de la Recherche Scientifique, 45071 Orléans Cedex 02, France.
D. Massiot
Affiliation:
CNRS, UPR 3079, CEMHTI, 1D Avenue de la Recherche Scientifique, 45071 Orléans Cedex 02, France.
G. Montavon
Affiliation:
Université de Nantes, SUBATECH, UMR CNRS 6457, Ecole des Mines de Nantes, 4 Rue Alfred Kastler, B.P. 20722, 44307 Nantes Cedex 03, France.
C. Mellier
Affiliation:
Université de Nantes, CNRS, UMR 6230, CEISAM, UFR Sciences et Techniques, 2 Rue de la Houssinière, B.P. 92208, 44322 Nantes Cedex 3, France.
B. Bujoli
Affiliation:
Université de Nantes, CNRS, UMR 6230, CEISAM, UFR Sciences et Techniques, 2 Rue de la Houssinière, B.P. 92208, 44322 Nantes Cedex 3, France.
Get access

Abstract

Combining Bisphophonates (BPs) and Calcium Phosphate Cement (CPC) to form a new medical device for the local treatment of Osteoporosis is a promising challenge. Our formulation was optimized from an apatitic-type CPC and we have shown that the best solution consists in introducing the bisphosphonate (Alendronate) in the calcium deficient apatite (CDA), a solid component of the cement, through a chemical exchange reaction. The cement obtained was characterized by 31P NMR and high frequency impedance for monitoring the CPC setting. The presence of Alendronate in the cement was also demonstrated by 31P NMR which has been also used to characterize the chemical transformation of α-TCP (main component of the apatitic cement) during the setting process. BP absorption/desorption experiments have been realized on cement blocks, under continuous flow condition, to model the release profile of the Alendronate. In vivo experiments showed promising results in terms of resorbability of the Alendronate–loaded cement while promoting new bone formation. The same methodology is considered to introduce gallium, a potential inhibitor of osteoclastic resorption, in a CPC formulation. First experiments have shown that gallium can be incorporated in calcium phosphate ceramics (i.e. β-TCP) where gallium is part of the network.

Keywords

Osteoporosisbiomaterialscalcium phosphate cement
Type
Articles
Information
MRS Online Proceedings Library (OPL) , Volume 1376: Symposium S11 – Biomaterials for Medical Applications , 2012 , imrc11-1376-s11-o7
Copyright
Copyright © Materials Research Society 2012

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1. Bouler, J.-M., Bujoli, B., Janvier, P., Khairoun, I., Argenson, J.-N., Patent WO2008098959 (2008).Google Scholar
2. Josse, S., Faucheux, C., Soueidan, A., Grimandi, G., Massiot, D., Alonso, B., Janvier, P., Laïb, S., Pilet, P., Gauthier, O., Daculsi, G., Guicheux, J., Bujoli, B., Bouler, J.-M., Biomaterials 26, 2073–2080 (2005).Google Scholar
3. Guicheux, J., Soueidan, A., Bouler, J.-M., Bujoli, B., Janvier, P., Drug Discovery Today 10, 156–157 (2005).Google Scholar
4. Schnitzler, V., Fayon, F., Despas, C., Khairoun, I., Mellier, C., Rouillon, T., Massiot, D., Walcarius, A., Janvier, P., Gauthier, O., Montavon, G., Bouler, J.-M., Bujoli, B., Acta Biomaterialia 7(2), 759–770 (2011).Google Scholar
5. Verron, E., Masson, M., Khoshniat, S., Duplomb, L., Wittrant, Y., Baud’huin, M., Badran, Z., Bujoli, B., Janvier, P., Scimeca, J.-C., Bouler, J.-M., Guicheux, J., Bristish Journal of Pharmacology 159(8), 1681–1692 (2010).Google Scholar
6. Mellier, C., Fayon, F., Schnitzler, V., Deniard, P., Allix, M., Quillard, S., Massiot, D., Bouler, J.-M., Bujoli, B. and Janvier, P., Inorganic Chemistry 50, 8252–8260 (2011).Google Scholar